Drospirenone and ethinyl estradiol and Norelgestromin and ethinyl estradiol interaction
Drospirenone and ethinyl estradiol and Norelgestromin and ethinyl estradiol: both prescribing labels flag this combination with the strongest language, such as a contraindication, a boxed warning, or an instruction to avoid it.
Do not combine without a prescriber's guidance. The label language below is the strongest FDA uses.
What the FDA labels say
From the Norelgestromin and ethinyl estradiol label · effective 2026-04-16
WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS and CONTRAINDICATED IN WOMEN WITH A BMI |GTE 30 kg/m2 • Cigarette Smoking and Serious Cardiovascular Events Cigarette smoking increases the risk of serious cardiovascular events from hormonal contraceptive use.
Cigarette smoking increases the risk of serious cardiovascular events from combination hormonal contraceptive (CHC) use.
…Populations ( 8.6 ) and Clinical Pharmacology ( 12.3 )] ● Undiagnosed abnormal uterine bleeding [see Warnings and Precautions ( 5.9 )] ● Pregnancy, because there is no reason to use hormonal contraceptives during pregnancy [see Warnings and Precautions ( 5.10 ) and Use in Specific Populations ( 8.1 )] ● Current diagnosis of, or history of, breast cancer, which…
Breast cancer or other estrogen- or progestin-sensitive cancer ( 4 )
Consider an alternate contraceptive method for women with uncontrolled dyslipidemia.
From the Drospirenone and ethinyl estradiol (Yaz) label · effective 2025-05-29
COCs containing DRSP may be associated with a higher risk of venous thromboembolism (VTE) than COCs containing levonorgestrel or some other progestins.
Table 2: Estimates (Hazard Ratios) of Venous Thromboembolism Risk in Current Users of Yasmin Compared to Users of Oral Contraceptives that Contain Other Progestins Epidemiologic Study (Author, Year of Publication) Population Studied Comparator Product (all are low-dose COCs; with ≤ 0.04 mg of EE) Hazard Ratio (HR) (95% CI) i3 Ingenix (Seeger 2007) Initiators,…
Effects of Other Drugs on Combined Oral Contraceptives Substances diminishing the efficacy of COCs: Drugs or herbal products that induce certain enzymes, including cytochrome P450 3A4 (CYP3A4), may decrease the effectiveness of COCs or increase breakthrough bleeding.
Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.
Open in the checkerNot medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.